TelyRx Holdings Inc. experienced a notable jump in its stock price, reflecting investor confidence.
In yesterday's trading session, TelyRx Holdings Inc. saw its stock price increase by 6.25%, closing at CA$2.55. This upward movement is a positive signal for investors following the company's recent financial performance.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$63.82M
52W high
$4.25
52W low
$2.00
1W change
+11.35%
Analyst Price Targets
Based on analyst covering TELY · as of Sep 17, 2026
Wall Street analysts forecast TELY stock price to rise 135.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+135.3% Upside
Current Price
C$2.55
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
64.2%
Annualized
90-Day Vol
88.9%
Annualized
Trend (90d)
+25.5%
Annualized drift
90d Mean
C$2.79
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.63 | C$2.11 – C$3.28 |
| 60 trading days | C$2.71 | C$1.98 – C$3.71 |
| 90 trading days | C$2.79 | C$1.90 – C$4.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The surge in TelyRx's stock price may indicate growing investor optimism, especially in light of its significant revenue growth reported in recent quarters.
6.25% Increase in Stock Price
TelyRx's stock price rose by CA$0.15, reflecting a strong performance in yesterday's trading session.
Bull case
The company recently announced impressive financial results, with revenue rising to CA$42.9 million for the year ended December 31, 2025, up from CA$9.5 million in 2024. This growth is likely attracting more interest from investors.
Bear case
Despite the positive movement, TelyRx still faces challenges. The company reported a net loss in recent quarters, which might raise concerns about its long-term profitability.
Recent Financial Performance
Advertisement
TelyRx announced a remarkable revenue increase to CA$42.9 million for the year ended December 31, 2025, up from CA$9.5 million in 2024. This impressive growth likely contributed to the stock's surge yesterday, as investors reacted positively to the company's performance.
Market Reactions
The stock's increase of 6.25% in yesterday's session reflects growing confidence among investors in TelyRx's potential. However, it's essential to consider the company's ongoing challenges, including a recent net loss, which could temper some of this optimism.
Looking Ahead
As TelyRx continues to navigate its growth trajectory, investors will be closely monitoring upcoming financial results and market developments. For more insights, check out the TelyRx stock page to stay updated on performance and news.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
